A Retrospective Real-World Analysis Demonstrating the Value of Azstarys for Patients With Attention-Deficit Hyperactivity Disorder

Abstract: Aim: To quantify the value of Azstarys (serdexmethylphenidate/dexmethylphenidate) for patients with attention-deficit hyperactivity disorder (ADHD) with real-world data from the large-scale Komodo® Healthcare Map database. Methods: Retrospective analyses were performed on data from open and closed insurance claims datasets spanning ~15 months (January 2021 to March 2022) to evaluate treatment patterns and use in ADHD patients. Patients were identified based on the diagnosis of ADHD (≥2 International Classification of Diseases-10 codes for ADHD) or through a fulfilled prescription for Azstarys. Patients with at least 90 days stability on Azstarys were analyzed for treatment patterns. Results: Of the 3,568,005 patients with ADHD, 3367; 810,582; 1,045,162; and 943,825; were Azstarys, methylphenidate long-acting (MLA), amphetamine long-acting (ALA), and lisdexamfetamine users, respectively. In the Azstarys, MLA, ALA, and lisdexamfetamine, cohorts, the mean ages of patients were 19, 17, 27, and 25, years, respectively; 68%, 74%, 33%, and 42%, of patients were aged